ClinicalTrials.gov ID NCT05161988 Sponsor: Assiut University Information provided by Fatma alzahraa Mustafa Abdelbary Thabet, Assiut University (Responsible Party) Study Overview Brief Summary Assessment of serum Interleukin 26 level in SLE patients and compare it with healthy controls. Association of serum interleukin 26 with SLE activity and severity. Detailed Description Systemic [READ MORE]
ClinicalTrials.gov ID NCT05693727 Sponsor: Assiut University Information provided by Mona Adel, Assiut University (Responsible Party) Study Overview Brief Summary To evaluate the ability of cancer ratio and pleural fluid markers to discriminate between malignant and non malignant effusion Detailed Description Pleural effusion is a common clinical entity affecting approximately 1.5 [READ MORE]
1) Estimation of the Tissue and Serum Levels of Interleukin (IL) -35 in Mycosis Fungoides: a Case Control Study | 2) Impact of Smoking on Salivary Interleukin (IL)-39, IL-41, IL-1β, TNF-α Levels in Periodontal Disease | 3) Targeting IL-17A for Treatment-Resistant Depression [READ MORE]
1) Effects of Interleukin (IL)-17A Inhibition on Idiopathic Subglottic Stenosis (ClinicalTrials.gov ID NCT05309616) | 2) Assessment of Serum interleukin10 Level in Patients With Immune Thrombocytopenic Purpura at Sohag University Hospital (ClinicalTrials.gov ID NCT05835050) | 3)Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma (DiTuSarc) (ClinicalTrials.gov ID NCT05080790) [READ MORE]
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma
New CSF Biomarkers for Alzheimer’s Disease (BioAD)
Interleukin and Autoantibodies in Myasthenia Gravis [READ MORE]
CSF Protein Markers as Prognostic Indicators of the Response to CSF Shunt in Normotensive Hydrocephalus | GM-CSF for Reversal of immunopAralysis in pediatriC sEpsis-induced MODS Study (GRACE) | Granulocyte-Macrophage Stimulating Factor (GM-CSF) in Peripheral Arterial Disease (GPAD-3) [READ MORE]
Human Interferon α1b Inhalation Solution Against Respiratory Syncytial Virus in Children With Lower Respiratory Tract Infections | Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma | Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma [READ MORE]
Interferon-α for TP53 Myeloid Malignancy Post Allo-HSCT | MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera (MITHRIDATE) | Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression (IPOS) [READ MORE]
Pegylated Interferon Lambda for Treatment of COVID-19 Infection | Proportion of Clinical Improvement & Type 1 Interferon (IFN) Score Changes in Idiopathic Uveitis Patients With Interferon Gamma Release Assay (IGRA) Positive | Allogeneic Hematopoietic Cell Transplantation With Pegylated Interferon Alfa-2a for Primary and Secondary Myelofibrosis (ATIOM) [READ MORE]
Blocking TNF to Potentiate the ICI-dependent Immune Awakening in Melanoma (ATPIC) | Effectiveness of Zidovudine vs. Zidovudine Plus Alpha Interferon vs. Interferon for Treatment of HIV | Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia [READ MORE]
International Cytokine & Interferon Society, Copyright 2024 Website Design by Rhema Association Management | Privacy Policy
